Chronic Myeloid Leukemia 2010: Where Are We Now and Where Can We Go?
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chronic Myeloid Leukemia 2010: Where Are We Now and Where Can We Go?
Authors
Keywords
-
Journal
Hematology-American Society of Hematology Education Program
Volume 2010, Issue 1, Pages 122-128
Publisher
American Society of Hematology
Online
2011-01-17
DOI
10.1182/asheducation-2010.1.122
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
- (2010) Deborah L. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase
- (2010) John M. Goldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
- (2009) M. C. Muller et al. BLOOD
- Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
- (2009) S. Branford et al. BLOOD
- A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
- (2009) S. K. McWeeney et al. BLOOD
- Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
- (2009) S. Saussele et al. BLOOD
- Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
- (2009) G. Rosti et al. BLOOD
- The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data
- (2009) V. G. Oehler et al. BLOOD
- Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
- (2009) Michele Baccarani et al. BLOOD
- Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily
- (2009) Hagop Kantarjian et al. CANCER
- Risk score for outcome after allogeneic hematopoietic stem cell transplantation
- (2009) Alois Gratwohl et al. CANCER
- The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up
- (2009) F. Palandri et al. HAEMATOLOGICA
- Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
- (2009) D. Milojkovic et al. HAEMATOLOGICA
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
- (2008) C. S. Tam et al. BLOOD
- Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
- (2008) S. Dulucq et al. BLOOD
- European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
- (2008) D. Marin et al. BLOOD
- Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
- (2008) F. Palandri et al. HAEMATOLOGICA
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
- (2008) Hugues de Lavallade et al. JOURNAL OF CLINICAL ONCOLOGY
- A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
- (2008) C M Lucas et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started